je.st
news
Tag: drug
Tyme Technologies, Inc. Receives FDA Acceptance Of Investigational New Drug Application For Oncology Drug Candidate, SM-88
2015-11-03 04:55:30| drugdiscoveryonline News Articles
Tyme Technologies, Inc., a research and development company operating through its wholly-owned subsidiary, Tyme Inc., focused on development and eventual commercialization of oncology products, announced recently that the U.S
Tags: application
drug
technologies
acceptance
Bruker Introduces The Molecular Drug Imager Solution For Small Molecule Drug Discovery And Development
2015-11-03 03:49:20| drugdiscoveryonline Home Page
At the 10th International Society for the Study of Xenobiotics (ISSX) meeting, Bruker recently announced the novel Molecular Drug Imagersolution for pre-clinical drug and metabolite imaging
Tags: small
development
solution
drug
PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
2015-11-03 03:42:29| drugdiscoveryonline Home Page
PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)
Tags: corporation
drug
submission
announces
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Advanced Colorectal Cancer
2015-11-02 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
food
administration
drug
Drug Maker Valeant Abandons 'Phantom Pharmacy'
2015-10-31 09:03:55| Biotech - Topix.net
Valeant Pharmaceuticals, a company that has come under intense scrutiny for its drug prices, has cut ties with Philidor following accusations that it was a "phantom pharmacy" used solely to artificially boost sales. Valeant said Friday that the mail-order pharmacy has informed the company that it will shut down as soon as possible.
Tags: drug
maker
pharmacy
phantom
Sites : [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] next »